All News
Predicting Treatment Response in Inflammatory Muscle Disorders
Rheumatologists looking for clues to whether their patients with certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study appearing in Arthritis Care & Research.
Read Article
BMI Most Impairs Treatment Response in Rheumatoid Arthritis
Using a large cohort of rheumatoid arthritis (RA) patients, Tumor-Necrosis Factor inhibitors (TNFi) were compared to non-TNFi biologic therapies and showed that poorer responses were seen in obese and underweight patients, with no clear superiority of non-TNFi therapy over TNFi therapy in an
Read Article
Rheumatoid Arthritis Nonadherence is Multifactorial
The consequences of medication non-adherence (NA) in rheumatoid arthritis (RA) care are numerous and damaging. A 6-month prospective cohort study of RA patients shows NA to vary according to drug type and be related to psychological, communicational, logistic, sociodemographic or clini
Read Article
Hand OA and Heroes in Rheumatology (2.11.2022)
Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.
Read Article
ACR Updates Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With COVID
A Task Force from the ACR has provided an updated (version 3) guidance for the diagnosis and management of Multisystem Inflammatory Syndrome in Children (MIS-C), a COVID related condition characterized by fever, inflammation, and multiorgan dysfunction.
Read Article
Methotrexate Side Effects
Data came from the UK Rheumatoid Arthritis Medication Study (RAMS), a prospective cohort of early RA patients starting methotrexate (MTX) shows that in the first year, adverse events (AE) were common, but not serious.
Read Article
Healthy Diets Prevent Gout in Women
A prospective cohort from the Nurses’ Health Study has demonstrated that eating a healthy diet results in a 12% to 32% lower risk of incident gout and an even greater risk reduction (65% to 68%) when combined with normal weight and avoiding diuretics.
Read Article
The Last Word on JAK Inhibitor Safety & 1133 Study (1.28.2022)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week a trifecta of Gout reports and the last word on the ORAL Surveillance study...
Read Article
Risk vs. Benefit Lessons from the ORAL Surveillance Study
In an editorial in the current edition of the NEJM, Dr. Jasvinder Singh comments on the Oral Surveillance trial (Ytterberg et al.), a 4-year randomized, open-label, noninferiority, postauthorization, safety end-point trial, in high risk active rheumatoid arthritis patients over age 50 years.
Read Article
MMWR: Booster Vaccine Efficacy in Immunosuppressed Patients
For adults aged ≥18 years who received 2 doses of an mRNA COVID-19 vaccine, a third dose increased vaccine effectiveness (prevention of hospitalization) among adults without (82% to 97%) and with immunocompromising conditions (69% to 88%), with near similar efficacy.
Read Article
Physical Therapy is More Cost-Effective than Intraarticular Steroids in Knee OA
A randomized trial compared the incremental cost-effectiveness of physical therapy and intra-articular glucocorticoid (IA GC) injection as initial treatment for knee osteoarthritis showed that physical therapy gained more quality-adjusted life-years compared with those receiving glucocortico
Read Article
Allopurinol Safety in CKD Patients
A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality.
Read Article
3rd Vaccine Dose May Benefit ANCA-Associated Vasculitis Patients
ARD has publish a prospective, multicenter, observational study of vaccination outcomes in antineutrophil cytoplasmic antibodies associated vasculitis (AAV) patients, showing that AAV patients may not be adequately protected after standard two-dose COVID-19 vaccination, but that a third
Read Article
Herpes Zoster Vaccination in Immunocompromised Adults
The CDC's Advisory Committee on Immunization Practices (ACIP) recently recommended and approved two doses of the recombinant zoster vaccine (RZV, AKA Shingrix) for prevention of herpes zoster and complications in immunodeficient or immunosuppressed adults aged ≥19 years.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
